Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company, has announced the publication of a new research study investigating the role of immune dysfunction in Parkinson's Disease $(PD)$. This study, partially funded by Coya and led by scientific advisors Dr. Aaron Thome and Dr. Stanley H. Appel, explores the correlation between inflammation, oxidative stress, and the progression of PD. Published in the journal Frontiers of Immunology, the research highlights the upregulation of pro-inflammatory cytokine transcripts such as interleukin 6 (IL-6) and interleukin 1 beta (IL-1b) in PD patients, with increased expression correlating to advanced PD stages. These findings support the dual immunomodulatory approach of Coya's investigational therapy, COYA 302, which aims to enhance regulatory T cell function and suppress inflammation. Results from this cross-sectional study have already been presented in the publication.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。